14 June 2016
(“NetScientific” or the “Group”)
NetScientific hosts Capital Markets Day to outline its strategy and showcase its portfolio of assets
London, UK – 14 June 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is today hosting a Capital Markets Day in London to outline the comprehensive strategy for the company and provide further detail on its portfolio companies and their path to value creation.
Netscientific has undergone a transformation, with a rationalisation of its portfolio and restructuring of the management team, resulting in a streamlined group focused on holding majority positions and delivery and maximising shareholder value from its investments in digital health, diagnostics and therapeutics.
At the event in London today, the Company’s Chairman, Sir Richard Sykes, and Chief Executive, Francois Martelet, will outline the next steps for NetScientific in maximising value from its portfolio companies. Representatives of the companies will also provide a detailed overview of the companies, the changing landscape in digital health, diagnostics and therapeutics, and their respective strategies for value realisation. The Capital Markets Day will be held at 85 Gresham Street, London EC2V 7NQ, from 12pm until 5pm. The event will conclude with a question and answer session and networking. Presentations from the Capital Markets Day will be made available via the Company’s website after the event.
Sir Richard Sykes, Chairman of NetScientific, said: “NetScientific’s management team and portfolio focus have been totally revitalised under the leadership of Francois Martelet. We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation. We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value.”
Presenters at the Netscientific Capital Markets Day will include:
· Sir Richard Sykes Chairman, Netscientific
· Francois Martelet CEO, Netscientific
· Gene Walther CEO, Vortex Biosciences
· Steve Curd CEO, Wanda
· Larry Cohen CEO, Glycotest
· Frank K Bedu Addo CEO, PDS Biotechnology
· Dr David Ribeiro CEO, ProAxsis
– Ends –
For more information, please contact:
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Investec (NOMAD and broker)
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7597 4000
Consilium Strategic Communications
Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net.